Heterocyclic Scaffolds: Centrality in Anticancer Drug Development

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|16|7|711-734

ISSN： 1389-4501

Source： Current Drug Targets, Vol.16, Iss.7, 2015-01, pp. : 711-734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Cancer Drug Discovery and Development Summit

By Blakey David C  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1577-1582

Informa Healthcare

Access to resources Recommend Favorite

Promise and challenges in drug discovery and development of hybrid anticancer drugs

By Gediya Lalji K   Njar Vincent CO  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 11, 2009-11 ,pp. : 1099-1111

Informa Healthcare

Access to resources Recommend Favorite

A Novel Candidate Compound with Urethane Structure for Anticancer Drug Development

By  

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 69-76

Bentham Science Publishers

Access to resources Recommend Favorite

The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development

By  

Current Cancer Drug Targets, Vol. 4, Iss. 3, 2004-05 ,pp. : 235-256

Bentham Science Publishers

Access to resources Recommend Favorite

Status of Non-Classical Mononuclear Platinum Anticancer Drug Development

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 11, 2009-10 ,pp. : 1357-1366

Bentham Science Publishers

Access to resources Recommend Favorite